Dr. Reddy's Laboratories Ltd.

Financial

	Dr. Reddy's Lab	Mankind Pharma	Torrent Pharma
Operational Metrics
Pharmaceutical Sector
Number of ANDA's Filed in USA	361.0 .	60.0 .	168.0 .
Number of ANDA's Approved By USFDA	288.0 .	44.0 .	132.0 .
Domestic Sales Growth - YoY	11.1 %	n/a	14.1 %
Global DMFs filed	1251.0 .	n/a	n/a
R&D as a % of Total Sales	8.5 %	2.15 %	5.1 %
Financials
5 yr Average ROE	14.9 %	23.46 %	20.0 %
5yr average Equity Multiplier	1.41	1.37	2.34
5yr Average Asset Turnover Ratio	0.77	0.95	0.65
5yr Avg Net Profit Margin	14.03 %	17.9 %	13.21 %
Price to Book	3.05	7.29	14.66
P/E	18.07	51.21	58.24
5yr Avg Cash Conversion Cycle	64.1 Days	-44.05 Days	-189.03 Days
Inventory Days	75.39 Days	58.78 Days	54.5 Days
Days Receivable	99.54 Days	24.18 Days	41.38 Days
Days Payable	102.35 Days	130.75 Days	318.84 Days
5yr Average Interest Coverage Ratio	34.06	56.97	5.79
5yr Avg ROCE	19.83 %	30.07 %	23.72 %
5yr Avg Operating Profit Margin	21.19 %	24.6 %	29.52 %
5 yr average Debt to Equity	0.12	0.05	0.83
5yr CAGR Net Profit	22.45 %	13.17 %	10.08 %
5yr Average Return on Assets	10.71 %	17.12 %	8.58 %
Shareholdings
Promoter Holding	26.64 %	72.7 %	68.31 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-0.08 %	-3.8 %	-2.94 %
Change in Mutual Fund Holding (3 Yrs)	-1.23 %	5.84 %	-2.45 %

Business

	Dr. Reddy's Lab	Mankind Pharma	Torrent Pharma
Product Wise Break-Up	Product Wise Break-Up Formulations 86.31 Pharmaceutical 13.52 Proprietary 0.17 Urology 0 Neuro/CNS 0 Pain/Analgesics 0 Gynaecology 0 Dermatology 0 Anti-Diabetic 0 Respiratory 0 VMN 0 Gastro - Intestinal 0 Cardiovascular 0 Anti-infectives 0 US Formulations 0 Domestic formulations 0 Contract Manf. 0 Brazil/Latam 0 Germany/Europe 0	Product Wise Break-Up Contract Manf. 0 Neuro/CNS 5.0 Proprietary 0 Germany/Europe 0 Domestic formulations 0 Respiratory 8.0 Gastrointestinal 9.0 Anti-infectives 14.0 Cardiovascular 15.0 US Formulations 0 Dermatology 5.0 Urology 2.0 Gynaecology 10.0 VMN 8.0 Brazil/Latam 0 Formulations 0 Anti-Diabetic 9.0 Pharmaceutical 0 Pain/Analgesics 4.0 Others 11.0	Product Wise Break-Up Contract Manufacturing 6.15 Neuro/CNS 0 Proprietary 0 Germany 13.15 Domestic Formulations 42.15 Respiratory 0 Gastro - Intestinal 0 Anti-infectives 0 Cardiovascular 0 US Formulations 20.71 Dermatology 0 Urology 0 Gynaecology 0 VMN 0 Brazil 8.98 Formulations 0 Anti-Diabetic 0 Pharmaceutical 0 Pain/Analgesics 0 Others 8.86
Location Wise Break-Up	Location Wise Break-Up USA 48.56 India 17.36 Russia 7.99 Nepal 0 Sri Lanka 0 Bangladesh 0 Germany 0 Brazil 0 Others 26.09	Location Wise Break-Up USA 0 Russia 0 India 86.0 Sri Lanka 0 Brazil 0 Germany 0 Bangladesh 0 Nepal 0 Others 14.0	Location Wise Break-Up USA 10.21 Russia 0 India 52.21 Sri Lanka 0 Brazil 11.86 Germany 9.67 Bangladesh 0 Nepal 0 Others 16.05
Operating Profit Break-Up	Operating Profit Break-Up Global Generics 94.57 Pharmaceutical Services and Active Ingredients 5.34 Proprietary Products 0.08 Others 0.01	-	-
Therapeutic Area Break-Up	Therapeutic Area Break-Up Oncology 27.53 Central Nervous System (CNS) 12.12 Pain Management 9.77 Gastro Intestinal 9.52 Respiratory 7.04 Cardiac Science 6.65 Anti-Infective 6.48 Gynae 0 Anti-infective 0 Pain 0 Anti- diabetic 0 CNS 0 Gastro-intestinal 0 Cardiac 0 Rest 0 VMN 0 Others 20.89	-	Therapeutic Area Break-Up Respiratory 0 Cardiac Science 26.0 CNS 15.0 Pain Management 0 Anti-Infective 0 Pain Management 7.0 Anti - Diabetes 9.0 Rest 2.0 Anti-Infective 3.0 Gynecology 2.0 Gastro Intestinal 17.0 Central Nervous System (CNS) 0 Gastro Intestinal 0 Cardiac Science 0 VMN 12.0 Oncology 0 Others 7.0
Asset Break-Up	Asset Break-Up India 80.24 Switzerland 8.45 USA 2.37 Others 8.94	-	Asset Break-Up USA 0.32 Switzerland 0 India 96.58 Others 3.1

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Ltd.

SIGN UP FOR FREE